Pacific Biosciences of California Inc (NASDAQ:PACB) has a beta value of 1.84 and has seen 1.43 million shares traded in the recent trading session. The company, currently valued at $913.71M, closed the recent trade at $3.41 per share which meant it gained $0.06 on the day or 1.79% during that session. The PACB stock price is -326.69% off its 52-week high price of $14.55 and 5.87% above the 52-week low of $3.21. If we look at the company’s 10-day average daily trading volume, we find that it stood at 6.29 million shares traded. The 3-month trading volume is 8.86 million shares.
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
Sporting 1.79% in the green today, the stock has traded in the red over the last five days, when the PACB stock price touched $3.41 or saw a rise of 6.32%. Year-to-date, Pacific Biosciences of California Inc shares have moved -65.24%, while the 5-day performance has seen it change -6.58%. Over the past 30 days, the shares of Pacific Biosciences of California Inc (NASDAQ:PACB) have changed -25.71%. Short interest in the company has seen 45.57 million shares shorted with days to cover at 4.67.
Pacific Biosciences of California Inc (PACB) estimates and forecasts
Figures show that Pacific Biosciences of California Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -58.52% over the past 6 months, with this year growth rate of 9.01%, compared to 13.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 25.00% and 7.10% for the next quarter. Revenue growth from the last financial year stood is estimated to be 19.10%.
10 analysts offering their estimates for the company have set an average revenue estimate of $50.39 million for the current quarter. 10 have an estimated revenue figure of $56.81 million for the next quarter concluding in Jun 2024.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -9.76% over the past 5 years. Earnings growth for 2024 is a modest 14.46% while over the next 5 years, the company’s earnings are expected to decrease by -1.00%.
PACB Dividends
Pacific Biosciences of California Inc is expected to release its next earnings report between April 30 and May 06 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Pacific Biosciences of California Inc (NASDAQ:PACB)’s Major holders
Insiders own 2.80% of the company shares, while shares held by institutions stand at 101.76% with a share float percentage of 104.68%. Investors are also buoyed by the number of investors in a company, with Pacific Biosciences of California Inc having a total of 378 institutions that hold shares in the company. The top two institutional holders are ARK Investment Management, LLC with over 29.82 million shares worth more than $249.02 million. As of Sep 29, 2023, ARK Investment Management, LLC held 11.90% of shares outstanding.
The other major institutional holder is Vanguard Group Inc, with the holding of over 23.13 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $307.59 million and represent 9.23% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF. As of Sep 29, 2023, the former fund manager holds about 6.41% shares in the company for having 16.06 million shares of worth $134.09 million while later fund manager owns 11.56 million shares of worth $96.5 million as of Sep 29, 2023, which makes it owner of about 4.61% of company’s outstanding stock.
